Education
About Us
Working with TipRanks
Follow Us
Atossa Therapeutics (ATOS)
NASDAQ:ATOS
Total Valuation
Atossa Therapeutics has a market cap or net worth of $80.49M. The enterprise value is $48.35M.
Market Cap$80.49M
Enterprise Value$48.35M
Share Statistics
Atossa Therapeutics has 129,170,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding129,170,000
Owned by Insiders7.10%
Owned by Institutions0.02%
Financial Efficiency
Atossa Therapeutics’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -34.47%.
Return on Equity (ROE)-0.33
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-34.47%
Return on Capital Employed (ROCE)-0.34
Revenue Per Employee0.00
Profits Per Employee-2.01M
Employee Count15
Asset Turnover0.00
Inventory Turnover0.02
Valuation Ratios
The current PE Ratio of Atossa Therapeutics is -3.69. Atossa Therapeutics’s PEG ratio is -0.26.
PE Ratio-3.69
PS Ratio―
PB Ratio1.22
Price to Fair Value1.22
Price to FCF-5.29K
Price to Operating Cash Flow-5.30K
PEG Ratio-0.26
Income Statement
In the last 12 months, Atossa Therapeutics had revenue of 0.00 and earned -30.09M in profits. Earnings per share was -0.24.
Revenue0.00
Gross Profit-23.00K
Operating Income-31.38M
Pretax Income-30.09M
Net Income-30.09M
EBITDA-31.35M
Earnings Per Share (EPS)-0.24
Cash Flow
In the last 12 months, operating cash flow was -21.03M and capital expenditures -19.00K, giving a free cash flow of -21.05M billion.
Operating Cash Flow-21.03M
Free Cash Flow-21.05M
Free Cash Flow per Share-0.16
Dividends & Yields
Atossa Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.80
52-Week Price Change-54.93%
50-Day Moving Average0.72
200-Day Moving Average1.12
Relative Strength Index (RSI)46.14
Average Volume (3m)639.82K
Important Dates
Atossa Therapeutics upcoming earnings date is May 19, 2025, TBA Not Confirmed.
Last Earnings DateMar 25, 2025
Next Earnings DateMay 19, 2025
Ex-Dividend Date―
Financial Position
Atossa Therapeutics as a current ratio of 17.61, with Debt / Equity ratio of 0.00%
Current Ratio17.61
Quick Ratio17.33
Debt to Market Cap0.00
Net Debt to EBITDA2.82
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Atossa Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Atossa Therapeutics EV to EBITDA ratio is -0.72, with an EV/FCF ratio of -1.07K.
EV to Sales0.00
EV to EBITDA-0.72
EV to Free Cash Flow-1.07K
EV to Operating Cash Flow-1.07K
Balance Sheet
Atossa Therapeutics has $71.08M in cash and marketable securities with $189.00K in debt, giving a net cash position of -$71.08M billion.
Cash & Marketable Securities$71.08M
Total Debt$189.00K
Net Cash-$71.08M
Net Cash Per Share-$0.55
Tangible Book Value Per Share$0.72
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Atossa Therapeutics is $5.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.50
Price Target Upside759.38% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast15.09%